MAKE YOUR DIAGNOSIS

URETHRAL BLOCKAGE IN A MALE CAT:

Much More Than Expected

Thomas P. Keeshen, DVM Clifford R. Berry, DVM, DACVR Gary W. Ellison, DVM, MS, DACVS University of Florida

ASK YOURSELF

- ► How should this patient be treated?
- ► Should surgery be recommended, and if so, when?

History

A week earlier, because of a urethral obstruction, Ivan had been catheterized by the primary veterinarian and was hospitalized for 2 to 3 days. The cat was discharged on oral marbofloxacin (2 mg/kg PO q24h), meloxicam (0.1 mg/ kg PO q24h), and prazosin (0.5 mg/cat PO q12h), but he continued to have difficulty urinating at home; last known urination was 2 days before presentation.

Physical Examination

At initial examination, Ivan was alert and responsive with heart rate, respiratory rate, and temperature within normal limits. He was estimated to be 5% dehydrated and had a large, firm, nonexpressible bladder. He was sedated with 0.015 mg/kg IV of buprenorphine, 0.2

mg/kg IV of midazolam, and administered a total of 2.5 mL of propofol IV for urinary catheter placement. A 5-French red rubber catheter was placed with slight resistance and maintained in place with butterfly tape and stay sutures. A CBC, serum chemistry panel, and plain abdominal radiographs (Figure 1, page 31) were performed.

Diagnostic Results

Initial and subsequent laboratory data showed marked azotemia with elevations in potassium and phosphorus (Table, page 30). Urine culture and susceptibility tests were performed; there was no growth on final culture. A urinalysis was not run on initial presentation.



TABLE

SIGNIFICANT LABORATORY RESULTS

Variable	Initial	18 Hours Post Unblocking	3 Days Post Unblocking (1 Day Before First Surgery)	4 Days Post Unblocking (Day of First Surgery)	7 Days Post Unblocking (Day Before Second Surgery)	10 Days Post Unblocking (2 Days After Second Surgery)	Reference Range
BUN	>140	240	60	30	29	_	14-36
(mg/dL)							
CREATININE	>12.0	17.8	4.1	2.7	2.2	-	0.9-2.3
(mg/dL)							
POTASSIUM	9.17	6.5	3.5	4.64	4.0	-	3.9-5.1
(mg/dL)							
PHOSPHORUS	>16.1	18.1	2.9	-	-	-	3.2-6.0
(mg/dL)							
HEMATOCRIT	30%	11%	16%	18%	16%	10%	34%-51%

nitrogen, FAST = focused assessment with sonography for trauma,
FIC = feline
idiopathic cystitis,
PCV = packed cell
volume

DID YOU ANSWER?

- ▶ Fluid therapy is aimed at correcting dehydration, reversing elevated potassium, and replacing ongoing losses the patient will experience from post-obstructive diuresis. 1 Hyperkalemia can be corrected with IV fluids, insulin, and dextrose.² Calcium gluconate can also prevent some arrhythmias that can form secondary to hyperkalemia.² This cat was initially stabilized with a 20 mL/kg bolus of lactated Ringer's solution, 1 mL/kg of calcium gluconate (10%) IV, and 0.2 U/kg of regular insulin IM and maintained on lactated Ringer's solution and 2.5% dextrose at 3.2 mL/kg/h. Because of severe hematuria and
- dropping packed cell volume (PCV), Ivan received 2 units of crossmatched packed red blood cells on days 2 and 3 of hospitalization.
- ► Feline idiopathic cystitis is commonly associated with urethral obstruction in male cats.^{1,3,4} Because this patient had a previous episode of urethral blockage—and because the 2 episodes were close together—perineal urethrostomy was a valid option after correction of azotemia. Plain abdominal films should be taken in feline idiopathic cases to look for cystic or urethral calculi.5



▲ The urinary bladder appears large and there is bilateral renomegaly in this right lateral view; dystrophic mineralization is present in the right kidney.



▲ A large echogenic structure is present within the urinary bladder. Power Doppler image shows that there is no blood supply to this material within the urinary bladder.

Diagnosis

Feline idiopathic cystitis (FIC) associated with urethral obstruction with severe azotemia and associated anemia.

Initial Treatment & Outcome

Ivan was hospitalized with IV fluids to replace post-obstructive urinary losses and to manage dehydration, azotemia, and hyperkalemia. He also received 0.01 mg/kg of buprenorphine IV q8h. Antimicrobials were not admistered.

The 5-French red rubber urinary catheter was maintained for 3 days; following its removal, the patient produced urine, although he was still pollakiuric, mildly stranguric, and hematuric. An abdominal focused assessment with sonography for trauma (FAST) scan in the emergency room showed a large amount of debris thought to be clots within the urinary bladder. A routine perineal urethrostomy was performed 5 days after presentation.

Ivan initially recovered uneventfully from anesthesia and surgery. The night after his surgery, he was able to urinate without

manual expression of his urinary bladder, and he was still hematuric. The next morning, he was started on prazosin (0.5 mg PO q12h). Two days later, he was still able to urinate without aid. Hematuria persisted, and his bladder was moderately full but soft and nonpainful.

Return


The next morning, 3 days post-surgery, Ivan was seen straining within his cage. At examination, he had a large, firm, slightly painful urinary bladder, and only a few drops of bloody urine were produced on manual expression.

He was mildly tachycardic at 220 bpm. The rest of his vitals were within normal limits, and he had pink mucous membranes. A PCV and blood gas analysis 7 days after unblocking (Table) were within normal limits, but he was still anemic.

A 5-French red rubber catheter was easily passed into the urinary bladder, but urine was not recovered. The catheter was initially flushed with 3 mL and subsequently 12 mL of

ASK YOURSELF

- ► What findings support a new diagnosis?
- ▶ What are the treatment options? Is surgical treatment recommended, and, if so, when?



▲ There is a filling defect taking up the majority of the lumen of the urinary bladder as evidenced by only a thin strip of positive contrast medium present in the periphery of the urinary bladder.

BUN = blood urea sonography for trauma, FIC = feline idiopathic cystitis, PCV = packed cell



▲ A5 cm × 3 cm semifirm, rubbery structure is visible within the urinary bladder.

heparinized saline; only 3 mL and 12 mL, respectively, were recovered when aspirated. A lateral radiograph was repeated and was unchanged from the time of admission.

Additional diagnostic tests included abdominal ultrasound (Figure 2, previous page) and computed tomography (CT) scan with IV contrast media (Figure 3).

DID YOU ANSWER?

- ► Urinary bladder hematoma admixed with sandy calculi was suspected. The structure had no blood flow, which made a neoplastic process less likely. Given the findings of the previous abdominal FAST scan, a urinary bladder hematoma was the top differential.
- ► The choice was made to surgically remove the urinary bladder hematoma via cystotomy. The source of the blood was thought to be renal because of the size and severity of the clot. Ivan was likely continuing to bleed into his urinary tract over the course of his stay because he continued to exhibit hematuria and his PCV continued to drop. This suggested that a moderatesized bladder after the perineal urethrostomy was actually an organized blood clot, not urine, because there is minimal bleeding from the urinary tract after a perineal urethrostomy. Another option would have been to try to dissolve the clot with tissue plasminogen activator, as is done in humans⁶; however, given the size of the clot, surgery was decided to be the better option.

New Diagnosis

Suspected urinary bladder hematoma

Treatment

Abdominal laparotomy with cystotomy was performed as the patient was no longer azotemic and his PCV had stabilized around 16% after receiving crossmatched packed red cells (*Figure 4*). The structure was removed and submitted for histopathology. The diagnosis was an organized hematoma; numerous erythrocytes and moderate numbers of neutrophils and macrophages surrounded by a fibrin layer were seen. Cultures of the bladder hematoma and urine were negative.

Outcome

Ivan was managed postoperatively with a fentanyl CRI at 3 µg/kg/hr and prazosin 0.5 mg q8h. At discharge 2 days later, Ivan had a hematocrit of 10% and poorly regenerative anemia; however, he was bright, alert, and responsive with an excellent appetite and attitude. At 8 weeks after discharge, PCV was 39%, BUN and creatinine were 25 mg/dL and 2.1 mg/dL, respectively, and urine specific gravity was 1.020. In subsequent follow-up conversations with the owner, Ivan appears to have made a full recovery.

References

- 1. Cooper ES, Owens TJ, Chew DJ, Buffington CA. A protocol for managing urethral obstruction in male cats without urethral catheterization. JAVMA. 2010;237(11):1261-1266
- 2. DiBartola SP, de Morais HA. Disorders of potassium: Hypokalemia and hyperkalemia. In: DiBartola SP, ed. Fluid, Electrolyte, and Acid Base Disorders in Small Animal Medicine. 3rd ed. St. Louis, MO: Saunders Elsevier; 2006:91-121
- 3. Cooper ES. Controversies in the management of feline urethral obstruction. JVECC. 2015;25(1):130-137.
- 4. Defauw PA, Van de Maele I, Duchateau L, Polis IE, Saunders JH, Daminet S. Risk factors and clinical presentation of cats with feline idiopathic cystitis. J Feline Med Surg. 2011;13(12):967-975.
- MacPhail CM. Feline idiopathic cystitis. In: Fossum TW. Small Animal Surgery. 4th ed. St. Louis: Elsevier Mosby; 2014:777-779.
- 6. Ritch CR, Ordonez MA, Okhunov Z, et al. Pilot study of Alteplase (tissue plasminogen activator) for treatment of urinary clot retention in an in vitro model. J Endourol. 2009:23(8):1353-1357.



(milbemycin oxime·lufenuron·praziquantel)

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

SENTINEL® SPECTRUM® (milhemycin oxime/lufenuron/praziquantel) is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis*; for the prevention and control of flea populations (Ctenocephalides felis); and for the treatment and control of adult roundworm (Toxocara canis, Toxascaris leonina), adult hookworm (Ancylostoma caninum), adult whipworm (*Trichuris vulpis*), and adult tapeworm (*Taenià piśiformis*, *Echinococcus multilocularis* and *Echinococcus granulosus*) infections in dogs and puppies two pounds of body weight or greater and six weeks of age and older.

Dosage and Administration

SENTINEL SPECTRUM should be administered orally, once every month, at the minimum dosage of 0.23 mg/lb (0.5 mg/kg) milbemycin oxime, 4.55 mg/lb (10 mg/kg) lufenuron, and 2.28 mg/lb (5 mg/kg) praziquantel. For heartworm prevention, give once monthly for at least 6 months after exposure to mosquitoes

Dosage Schedule

3							
Body Weight	Milbemycin Oxime per chewable	Lufenuron per chewable	Praziquantel per chewable	Number of chewables			
2 to 8 lbs.	2.3 mg	46 mg	22.8 mg	One			
8.1 to 25 lbs.	5.75 mg	115 mg	57 mg	One			
25.1 to 50 lbs.	11.5 mg	230 mg	114 mg	One			
50.1 to 100 lbs.	23.0 mg	460 mg	228 mg	One			
Over 100 lbs.	Administer the appropriate combination of chewables						

To ensure adequate absorption, always administer SENTINEL SPECTRUM to dogs immediately after or in conjunction with a normal meal.

SENTINEL SPECTRUM may be offered to the dog by hand or added to a small amount of dog food. The chewables should be administered in a manner that encourages the dog to chew, rather than to swallow without chewing. Chewables may be broken into pieces and fed to dogs that normally swallow treats whole. Care should be taken that the dog consumes the complete dose, and treated animals should be observed a few minutes after administration to ensure that no part of the dose is lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended

Contraindications

There are no known contraindications to the use of SENTINEL SPECTRUM.

WarningsNot for use in humans. Keep this and all drugs out of the reach of children.

Precautions

Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention.

Prior to administration of SENTINEL SPECTRUM, dogs should be tested for existing heartworm infections. At the discretion of the veterinarian, infected dogs should be treated to remove adult heartworms. SENTINEL SPECTRUM is not effective against

Mild, transient hypersensitivity reactions, such as labored breathing, vomiting hypersalivation, and lethargy, have been noted in some dogs treated with milbemycin oxime carrying a high number of circulating microfilariae. These reactions are presumably caused by release of protein from dead or dying microfilariae.

Do not use in puppies less than six weeks of age

Do not use in dogs or puppies less than two pounds of body weight

The safety of SENTINEL SPECTRUM has not been evaluated in dogs used for breeding or in lactating females. Studies have been performed with milbemycin oxime and lufenuron alone.

The following adverse reactions have been reported in dogs after administration of milbemycin oxime, lufenuron, or praziquantel: vomiting, depression/lethargy, pruritus, urticaria, diarrhea, anorexia, skin congestion, ataxia, convulsions, salivation, and weakness

To report suspected adverse drug events, contact Virbac at 1-800-338-3659 or the FDA

Information for Owner or Person Treating Animal

Echinococcus multilocularis and Echinococcus granulosus are tapeworms found in wild canids and domestic dogs. E. multilocularis and E. granulosus can infect humans and cause serious disease (alveolar hydatid disease and hydatid disease, respectively). Owners of dogs living in areas where E. multilocularis or E. granulosus are endemic should be instructed on how to minimize their risk of exposure to these parasites, as well as their dog's risk of exposure. Although SENTINEL SPECTRUM was 100% effective in laboratory studies in dogs against *E. multilocularis* and *E. granulosus*, no studies have been conducted to show that the use of this product will decrease the incidence of alveolar hydatid disease or hydatid disease in humans. Because the prepatent period for *E. multilocularis* may be as short as 26 days, dogs treated at the labeled monthly intervals may become reinfected and shed eggs between treatments

Manufactured for: Virbac AH, Inc

P.O. Box 162059. Ft. Worth. TX 76161

NADA #141-333, Approved by FDA © 2015 Virbac Corporation. All Rights Reserved. SENTINEL and SPECTRUM are registered trademarks of Virbac Corporation.